Join Arrowhead Pharmaceuticals for a virtual analyst and investor event reviewing the new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) presented at the American Heart Association (AHA) Scientific Sessions 2023.

The event will feature presentations from three key opinion leaders in the treatment and management of lipid and lipoprotein disorders, who will discuss these data and their relevance as potential treatments for severe hypertriglyceridemia and mixed dyslipidemia in patients with atherosclerotic cardiovascular disease (ASCVD):

• Daniel Gaudet, MD, PhD, Professor of Medicine at Université de Montréal, who will discuss plozasiran in the context of the current treatment landscape for severe hypertriglyceridemia
• Børge Nordestgaard, MD, Professor & Chief Physician, Copenhagen University Hospital, University of Copenhagen, Denmark, who will discuss remnant cholesterol and its role in cardiovascular disease
• Steven Nissen, MD, Chief Academic Officer for the Heart and Vascular Institute at the Cleveland Clinic, who will discuss the potential of a cardiovascular outcomes study of plozasiran

A live question and answer will follow the formal presentations.